Semaglutide Dragon Pharma

£142.00

Semaglutide Dragon Pharma is a glucagon-like peptide-1 receptor agonist for metabolic research applications. Extensively studied for glucose homeostasis and appetite regulation pathways in laboratory models.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Semaglutide Dragon Pharma
Semaglutide Dragon Pharma
£142.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Research Applications and Mechanism

Semaglutide Dragon Pharma is a glucagon-like peptide-1 (GLP-1) receptor agonist peptide hormone widely investigated in metabolic research. This synthetic analogue of human GLP-1 demonstrates prolonged activity through structural modifications that enhance stability and half-life in preclinical models. Researchers at Stroid UK Shop examine its mechanism of action via selective binding to GLP-1 receptors, which are distributed throughout pancreatic beta cells, gastric tissue, and central nervous system regions involved in appetite regulation.

Laboratory Investigation Focus

Scientists investigate semaglutide’s effects on glucose-dependent insulin secretion and glucagon suppression in cell culture studies. The compound modulates gastric emptying rates and activates hypothalamic satiety pathways in animal models, making it valuable for metabolic dysfunction research. Studies examine its interaction with incretin receptor signaling cascades and downstream effects on cellular energy metabolism. Researchers studying metabolic modulators evaluate semaglutide alongside other compounds that influence energy expenditure and substrate utilization.

Technical Specifications

Semaglutide Dragon Pharma Research Specifications
Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight 4113.58 g/mol
CAS Number 910463-68-2
Classification GLP-1 receptor agonist peptide
Storage Conditions 2-8°C, protect from light
Solubility Water-soluble

Research laboratories studying metabolic pathways often examine semaglutide in conjunction with other peptide compounds from our peptides collection or selective modulators from SARMs research to understand comprehensive metabolic regulation mechanisms.

Research Compliance Statement

This semaglutide preparation is manufactured by Dragon Pharma exclusively for in-vitro research applications. The compound is intended solely for qualified research institutions and licensed laboratories conducting studies on metabolic pathways, GLP-1 receptor pharmacology, and incretin hormone mechanisms. This product is not approved for human consumption, therapeutic use, or any clinical applications outside of controlled laboratory environments.

Related